NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis $0.40 +0.05 (+14.71%) As of 07/2/2025 03:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Virpax Pharmaceuticals Stock (NASDAQ:VRPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Virpax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.35▼$0.4450-Day Range$0.22▼$0.4652-Week Range$0.13▼$84.75Volume4,271 shsAverage Volume201,655 shsMarket Capitalization$496.92 thousandP/E RatioN/ADividend YieldN/APrice Target$75.00Consensus RatingHold Company Overview Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Read More Virpax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreVRPX MarketRank™: Virpax Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingVirpax Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVirpax Pharmaceuticals has received no research coverage in the past 90 days.Read more about Virpax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirpax Pharmaceuticals has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.67% of the float of Virpax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVirpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virpax Pharmaceuticals has recently increased by 119.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirpax Pharmaceuticals does not currently pay a dividend.Dividend GrowthVirpax Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.67% of the float of Virpax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVirpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virpax Pharmaceuticals has recently increased by 119.58%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for VRPX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Virpax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.Read more about Virpax Pharmaceuticals' insider trading history. Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRPX Stock News HeadlinesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | Crypto 101 Media (Ad)Virpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comSee More Headlines VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed this year? Virpax Pharmaceuticals' stock was trading at $9.4975 at the beginning of the year. Since then, VRPX stock has decreased by 95.8% and is now trading at $0.4001. View the best growth stocks for 2025 here. When did Virpax Pharmaceuticals' stock split? Virpax Pharmaceuticals shares reverse split before market open on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virpax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Mullen Automotive (MULN), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS). Company Calendar Today7/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRPX CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$75.00 High Stock Price Target$75.00 Low Stock Price Target$75.00 Potential Upside/Downside+18,645.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,554.34% Return on Assets-338.29% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.24Miscellaneous Outstanding Shares1,242,000Free Float4,707,000Market Cap$496.92 thousand OptionableNot Optionable Beta1.49 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VRPX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.